Media ReleasesCellmid Limited

View All Cellmid Limited News

Cellmid Ltd, Newsletter - October 2013

Message from the CEO

Since our May 2013 newsletter we have made ten material announcements to the market with strong positive impact on our diagnostic, therapeutic and consumer health businesses. We have also released our annual report for the 2013 financial year  recently showing 300% increase in operational revenue and 20% reduction in loss, and our share price is up more than 100% this year.

In late May we settled the acquisition of Advangen Inc, Japan, taking control of the global rights to the FGF-5 inhibitor products for hair growth. Since then, we have increased sales in Australia and signed a major Japanese distribution agreement for 30,000 units of our products, representing over 40% of our expected annual revenue in that region. This momentum should continue as we pursue other markets and expect new territories signed up in 2014.

To view Newsletter please download PDF below:

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.